Evidence map›Paper›PMID 31099865›Full record

Observational studyJAMA network open2019

Viremia Trajectories of HIV in HIV-Positive Women in the United States, 1994-2017.

Seble G Kassaye, Cuiwei Wang, Joanne Michelle F Ocampo, Tracey E Wilson, Kathryn Anastos, Mardge Cohen, Ruth M Greenblatt, Margaret A Fischl, Igho Otofukun, Adaora Adimora and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in JAMA network open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Factors and Outcomes Associated With Viral Suppression Trajectory Group Membership Among Youth Transitioning From Pediatric to Adult HIV Care.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2022
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 1 country.

Seble G KassayeDepartment of Medicine, Georgetown University Medical Center, Washington, DC.
Cuiwei WangDepartment of Medicine, Georgetown University Medical Center, Washington, DC.
Joanne Michelle F OcampoDepartment of Medicine, Georgetown University Medical Center, Washington, DC.
Tracey E WilsonDepartment of Community Health Sciences, Downstate Medical Center School of Public Health, State University of New York, Brooklyn.
Kathryn AnastosDepartments of Medicine and Epidemiology & Population Health, Albert Einstein College of Medicine, Montefiore Health Systems, New York, New York.
Mardge CohenRuth M. Rothstein CORE Center, Stroger Hospital, Cook County Bureau of Health Services, Chicago, Illinois.
Ruth M GreenblattDepartment of Clinical Pharmacy, Schools of Pharmacy and Medicine, University of California, San Francisco.
Margaret A FischlDepartment of Medicine, University of Miami Miller School of Medicine, Miami, Florida.
Igho OtofukunDepartment of Medicine, Emory University, Atlanta, Georgia.
Adaora AdimoraDepartment of Medicine, University of North Carolina at Chapel Hill.
Mirjam-Colette KempfSchool of Nursing, University of Alabama at Birmingham, Birmingham.
Gerald B SharpNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Mary YoungDepartment of Medicine, Georgetown University Medical Center, Washington, DC.
Michael PlankeyDepartment of Medicine, Georgetown University Medical Center, Washington, DC.
Georgetown University · USGeorgetown University Medical Center · USAlbert Einstein College of Medicine · USEmory University · USNational Institutes of Health · USRuth M. Rothstein CORE Center · USSUNY Downstate Health Sciences University · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of Miami · USUniversity of North Carolina at Chapel Hill · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
Sex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
UNC MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146194 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Bradley Drummond, Michelle Floris-Moore · 2019 to 2026
$23.2M
University of North Carolina Womens Interagency HIV Study UNC WIHSU01AI103390 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ADIMORA, ADAORA A · 2013 to 2018
$11.0M
Georgetown-Howard Universities Center for Clinical and Translational Science (GHUKL2TR000102 · NCATS · GEORGETOWN UNIVERSITY · PI MELLMAN, THOMAS A, VERBALIS, JOSEPH G · 2012 to 2014
$1.7M
Georgetown-Howard Universities Center for Clinical and Translational Science (GHUKL2RR031974 · NCRR · GEORGETOWN UNIVERSITY · PI VERBALIS, JOSEPH G · 2010 to 2011
$711k
Acute Effects of Cannabis on Cognition and Mobility in Older HIV-Infected and Uninfected Women"R21AG059505 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SHARMA, ANJALI · 2018 to 2019
$318k
NCATS NIH HHS KL2 TR000102NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000454NCRR NIH HHS KL2 RR031974NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146204NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI103390NIA NIH HHS R21 AG059505
6 · The paper itself

Abstract

Importance: Viral suppression of HIV is an important treatment goal to decrease morbidity, mortality, and risk of transmission to others. Objective: To characterize longitudinal HIV viral load outcomes among women enrolled in the Women's Interagency HIV Study (WIHS). Design, Setting, and Participants: A prospective cohort study of HIV-positive women with semiannual study visits and a minimum of 5 follow-up visits was conducted from 1994 to 2017. The WIHS sites included in this analysis are in Brooklyn and Bronx, New York; Chicago, Illinois; San Francisco, California; and Washington, DC. Main Outcomes and Measures: Women were categorized into groups based on their probability of achieving viral load suppression below 200 copies/mL using logistic trajectory modeling. Multinomial regression analysis was used to identify factors associated with placement in the group with the highest probability of viremia. Results: At baseline, the mean (SD) age of the 1989 women was 36.9 (8.0) years, mean CD4+ T-lymphocyte count was 467/mm3, median (interquartile range) HIV RNA was 6200.0 (384.5-41 678.0) copies/mL, and 1305 women (65.6%) were African American. Three trajectory groups were identified with low (568 [28.6%]), intermediate (784 [39.4%]), and high (637 [32.0%]) probability of viremia above 200 copies/mL. The mean (SD) cumulative years of viral suppression were 18.7 (4.0) years, 12.2 (3.1) years, and 5.8 (2.9) years in the respective groups. Factors associated with high probability of viremia included younger age (odds ratio [OR]. 0.99; 95% CI, 0.98-0.99; P = .03), African American race (odds ratio [OR], 2.43; 95% CI, 1.75-3.37), P < .001), Hispanic race/ethnicity (OR, 1.50; 95% CI, 1.03-2.19; P = .04), increased levels of depressive symptoms (OR, 1.17; 95% CI, 1.01-1.36; P = .03), drug use (OR, 1.23; 95% CI, 1.01-1.51; P = .04), lower CD4+ T-lymphocyte counts (OR, 95% CI, 0.82; 0.80-0.85; P < .001), and unstable housing (OR, 1.25, 95% CI, 1.03-1.50; P = .02). Between 2015 and 2017, 71.2% of women demonstrated sustained viral suppression: 89.6% (310 of 346) of those with low viremia, 83.4% (346 of 415) with intermediate, and 35.2% (112 of 318) with high probability of viremia. Conclusions and Relevance: This longitudinal approach suggested that the probability of viremia decreased substantially over time for most participants, including among women with earlier histories of incomplete viral suppression. The findings from this study suggest that continued efforts are needed to address mental health, social, behavioral and structural factors that were identified as associated with high probability of HIV viremia over time.

Indexed as

AdultAntiviral AgentsFemaleHIV InfectionsHumansLongitudinal StudiesMiddle AgedProspective StudiesRisk FactorsUnited StatesViral LoadViremiaAntiviral Agents

Identifiers

PMID31099865
PMCPMC6537820
OpenAlexW2946247285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.